減量薬の需要により,Hims & Hersは売上を146億ドルに上昇させています. Hims & Hers raises its sales forecast to $1.46 billion, driven by demand for weight-loss drugs.

ウェルネスプラットフォームであるHims & Hersは,GLP-1のような減量薬の需要によって,今年の売上予測を146~1465億ドルに上げ,株価が上昇した. Hims & Hers, a wellness platform, has seen its shares rise after raising its sales forecast for the year to $1.46-$1.465 billion, driven by demand for weight-loss drugs like GLP-1s. 同社は3四半期に4億1,600万ドルの収益を報告し,昨年から77%増加し,収益性期待を上回った. The company reported $401.6 million in revenue for the third quarter, a 77% increase from last year, and surpassed profitability expectations. 提供の制限が続いている中で,来年,一般的なGLP-1,リラグルチドを導入する予定です. With over 2 million subscribers, Hims & Hers plans to introduce a generic GLP-1, Liraglutide, next year amid ongoing supply constraints.